Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Predictors of indeterminate IFN‐γ release assay in screening for latent TB in inflammatory bowel diseases

Predictors of indeterminate IFN‐γ release assay in screening for latent TB in inflammatory bowel... Eur J Clin Invest 2011; 41 (10): 1071–1076 Background IFN‐γ release assays (IGRA), widely used for latent tuberculosis screening prior to anti‐TNF‐α treatment, are limited by indeterminate results in patients under immunomodulatory (IM) therapy. The aim of our observational study was to delineate factors associated with indeterminate IGRA results. Methods A total of 190 patients with inflammatory bowel disease were included. IGRA was indeterminate if the result of IFN‐γ concentration was < 0·35 IU mL−1 for tuberculosis‐specific antigens and < 0·5 IU mL−1 for the positive control. Predictors for indeterminate results were delineated from multivariate logistic regression. Results IFN‐γ release assays was indeterminate in 26/190 (13·7%) patients. Indeterminate IGRA were associated with lower serum albumin levels (odds ratio (OR) 0·88, 95% confidence interval (CI) 0·79–0·96), lower absolute lymphocyte count (OR 0·39, 95% CI 0·18–0·75) and double IM therapy (OR 2·98, 95% CI 0·95–8·90). Sub‐analysis of IM therapy revealed an association of steroid therapy with indeterminate IGRA (OR 3·19, 95% CI 1·35–7·70). Hypoalbuminaemia increased the risk of indeterminate IGRA by (OR 2·97, 95% CI 1·03–8·61) and lymphopaenia by (OR 3·28, 95% CI 1·41–7·65). After a mean of 18·5 ± 14·4 days, retesting of IGRA in 18 patients with indeterminate results yielded 9 negative vs. 9 indeterminate results. Conclusions Our results reveal associations of indeterminate IGRA with low serum albumin levels and absolute lymphocyte count and double IM therapy. IGRA testing appears best to be performed prior to initiation of IM therapy in patients with inflammatory bowel disease. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Investigation Wiley

Loading next page...
 
/lp/wiley/predictors-of-indeterminate-ifn-release-assay-in-screening-for-latent-sAaeQ3J5z7

References (37)

Publisher
Wiley
Copyright
© 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation
ISSN
0014-2972
eISSN
1365-2362
DOI
10.1111/j.1365-2362.2011.02502.x
pmid
21413978
Publisher site
See Article on Publisher Site

Abstract

Eur J Clin Invest 2011; 41 (10): 1071–1076 Background IFN‐γ release assays (IGRA), widely used for latent tuberculosis screening prior to anti‐TNF‐α treatment, are limited by indeterminate results in patients under immunomodulatory (IM) therapy. The aim of our observational study was to delineate factors associated with indeterminate IGRA results. Methods A total of 190 patients with inflammatory bowel disease were included. IGRA was indeterminate if the result of IFN‐γ concentration was < 0·35 IU mL−1 for tuberculosis‐specific antigens and < 0·5 IU mL−1 for the positive control. Predictors for indeterminate results were delineated from multivariate logistic regression. Results IFN‐γ release assays was indeterminate in 26/190 (13·7%) patients. Indeterminate IGRA were associated with lower serum albumin levels (odds ratio (OR) 0·88, 95% confidence interval (CI) 0·79–0·96), lower absolute lymphocyte count (OR 0·39, 95% CI 0·18–0·75) and double IM therapy (OR 2·98, 95% CI 0·95–8·90). Sub‐analysis of IM therapy revealed an association of steroid therapy with indeterminate IGRA (OR 3·19, 95% CI 1·35–7·70). Hypoalbuminaemia increased the risk of indeterminate IGRA by (OR 2·97, 95% CI 1·03–8·61) and lymphopaenia by (OR 3·28, 95% CI 1·41–7·65). After a mean of 18·5 ± 14·4 days, retesting of IGRA in 18 patients with indeterminate results yielded 9 negative vs. 9 indeterminate results. Conclusions Our results reveal associations of indeterminate IGRA with low serum albumin levels and absolute lymphocyte count and double IM therapy. IGRA testing appears best to be performed prior to initiation of IM therapy in patients with inflammatory bowel disease.

Journal

European Journal of Clinical InvestigationWiley

Published: Oct 1, 2011

There are no references for this article.